Abliva AB

About:

Abliva develops medicines for the treatment of primary mitochondrial diseases.

Website: https://abliva.com/

Top Investors: IP Group, Vinnova, U.S. Department of Defense, Hadean Ventures, Congressionally Directed Medical Research Programs

Description:

Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly. The portfolio includes projects at different stages and ranges from early discovery phase to clinical phase.

Total Funding Amount:

$40.4M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Lund, Skane Lan, Sweden

Founded Date:

2000-01-01

Contact Email:

info(AT)abliva.com

Founders:

Eskil Elmér

Number of Employees:

1-10

Last Funding Date:

2022-05-31

IPO Status:

Public

Industries:

© 2025 bioDAO.ai